Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder TrialMarket Beat·13 hours agoALT+1.01%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·14 hours agoALT+1.01%OTLK-15.12%
ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinenceQuartr·15 hours agoALT+1.01%
Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUDTradingView·15 hours agoALT+1.01%
Biotech and CXO Clinical Momentum: 7 Core Companies Set for Late-2026 BreakoutsGlobal Report·Jul 9 at 05:02 AMBVS+6.10%ALT+1.01%
Altimmune shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $10 price target.benzinga_article·Jun 22 at 12:47 PMALT+1.01%
